Active — Not RecruitingPhase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

United States98 participantsStarted 2024-01-16

Plain-language summary

A study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD1705 in participants with dyslipidemia.

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Alanine aminotransferase \> 1.5 × upper limit of normal (ULN).
✕. Aspartate aminotransferase \> 1.5 × ULN.
✕. Total bilirubin \> ULN (Gilbert's syndrome).
✕. Estimated glomerular filtration rate \< 60 milliliter (mL)/minute/1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation 2021 (National Kidney Foundation).
✕. Hemoglobin \< lower limit normal (LLN).
✕. Systolic blood pressure (BP) ≤ 90 millimeters of mercury (mmHg) or \> 140 mmHg (Part A) or \> 150 mmHg (Part B).
✕. Diastolic BP \< 50 mmHg or \> 90 mmHg.
✕. Heart rate \< 45 or \> 90 beats per minute (bpm). Note: Blood pressure will be measured in triplicates and the mean value will be used. Where the values are outside the required range at admission, then based on medical history, one retest may be performed at this visit.

Number of participants with adverse events (AEs) and serious adverse events (SAEs)

Timeframe: Part A: From Screening (Day -60 to Day -2) until Day 113. Part B: From Screening until Day 141

NCT IDNCT06238466

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-12-01